General Atlantic LLC Centessa Pharmaceuticals PLC Transaction History
General Atlantic LLC
- $2.96 Billion
- Q1 2025
A detailed history of General Atlantic LLC transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, General Atlantic LLC holds 9,681,818 shares of CNTA stock, worth $155 Million. This represents 4.7% of its overall portfolio holdings.
Number of Shares
9,681,818
Previous 9,681,818
-0.0%
Holding current value
$155 Million
Previous $162 Million
14.15%
% of portfolio
4.7%
Previous 5.81%
Shares
2 transactions
Others Institutions Holding CNTA
# of Institutions
138Shares Held
124MCall Options Held
163KPut Options Held
816K-
Medicxi Ventures Management (Jersey) LTD20MShares$319 Million74.33% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$159 Million100.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.95MShares$111 Million0.19% of portfolio
-
Janus Henderson Group PLC London, X05.92MShares$94.5 Million0.05% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.34MShares$85.3 Million0.01% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $1.51B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...